Use of botulinum toxin type A in rheumatic diseases
https://doi.org/10.14412/1996-7012-2021-5-108-113
Abstract
The article presents an analysis of modern data on the antinociceptive effectiveness of botulinum toxin type A (BTA) in rheumatic diseases (RD). The prospects for the use of BTA in the treatment of pain in different RDs are discussed. We searched for publications in the Medline, Pubmed, Cochrane Library databases. Analysis of literature data has shown that BTA can become an additional method of pain management in many RDs.
Supporting agencies: The investigation has been conducted within scientific topic №0397-2020-0006 «Innovative technologies for the diagnosis and treatment of systemic connective tissue diseases».
About the Authors
O. N. Egorova
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
Olga Nikolaevna Egorova
34A, Kashirskoe Shosse, Moscow 115522
B. S. Belov
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
E. G. Sazhina
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
References
1. Breivik H, Collett B, Ventafridda V, et al. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain. 2006 May;10(4):287-333. doi: 10.1016/j.ejpain.2005.06.009.Epub 2005 Aug 10.
2. Ekusheva EV. Comorbid patient with chronic pain syndrome. Russkii meditsinskii zhurnal.2019;(9):44-8. (In Russ.).
3. http://www.who.int/nmh/Global_Atlas_of_Palliative_Care.pdf
4. Nasonova VA, Karateev AE. Symptomatic therapy for pain in rheumatic diseases: a place of aceclofenac. Sovremennaya revmatologiya = Modern Rheumatology Journal.2009;3(3):58-65. (In Russ.). doi: 10.14412/1996-7012-2009-560
5. Zhai S, Huang B, Yu K. The efficacy and safety of Botulinum Toxin Type A in painful knee osteoarthritis: a systematic review and meta-analysis. J Int Med Res. 2019 Dec 29: 300060519895868. doi: 10.1177/0300060519895868.
6. Kostenko EV, Konovalova ZN, Orlova OR, Khat'kova SE. Botulinum toxin in pain syndromes. Meditsinskii sovet. 2018;(1):58-63. (In Russ.).
7. Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinumtoxin type A. Neurotoxicology. 2005 Oct;26(5):785-93. doi: 10.1016/j.neuro.2005.01.017. Epub 2005 Jul 5.
8. Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol. 1993 Jan;33(1):48-56. doi: 10.1002/ana.410330109.
9. Gobel H, Heinze A, Heinze-Kuhn K, Austermann K. Botulinum toxin A in the treatment of headache syndromes and pericranial pain syndromes. Pain. 2001 Apr;91(3): 195-9. doi: 10.1016/S0304-3959(01)00292-5
10. Silberstein SD. Review of botulinum toxin type A and its clinical applications in migraine headache. Expert Opin Pharmacother. 2001 Oct;2(10):1649-54. doi: 10.1517/14656566.2.10.1649.
11. Aoki KR. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache. Jul-Aug 2003;43 Suppl 1: S9-15. doi: 10.1046/j.1526-4610.43.7s.3.x.
12. Gazerani P, Staahl C, Drewes AM, Arendt-Nielsen L. The effects of Botulinum Toxin type A on capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization. Pain. 2006 Jun;122(3):315-25. doi: 10.1016/j.pain.2006.04.014. Epub 2006 May 4.
13. Gazerani P, Pedersen NS, Staahl C, et al. Subcutaneous Botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin. Pain. 2009 Jan;141(1-2):60-9. doi: 10.1016/j.pain.2008.10.005. Epub 2008 Nov 11.
14. Artem'ev DV, Orlova OR, Morenkova AE. The use of botox in medical practice. Nevrologicheskii zhurnal.2000;5(4):46-51. (In Russ.).
15. Whitemarsh RC, Tepp WH, Bradshaw M, et al. Characterization of botulinum neurotoxin A subtypes 1 through 5 by investigation of activities in mice, in neuronal cell cultures, and in vitro. Infect Immun. 2013 Oct;81(10): 3894-902. doi: 10.1128/IAI.00536-13. Epub 2013 Aug 5.
16. Pier CL, Chen C, Tepp WH, et al. Botulinum neurotoxin subtype A2 enters neuronal cells faster than subtype A1. FEBS Lett. 2011 Jan 3;585(1):199-206. doi: 10.1016/j.febslet.2010.11.045. Epub 2010 Nov 30.
17. Akaike N, Shin MC, Wakita M, et al. Transsynaptic inhibition of spinal transmission by A2 botulinum toxin. J Physiol. 2013 Feb 15;591(4):1031-43. doi: 10.1113/jphysiol.2012.242131. Epub 2012 Oct 29.
18. Mahowald ML, Singh JA, Dykstra D. Long term effects of intra-articular botulinum toxin A for refractory joint pain. Neurotox Res. 2006 Apr;9(2-3):179-88. doi: 10.1007/BF03033937.
19. Singh JA, Mahowald ML. Intra-articular botulinum toxin A as an adjunctive therapy for refractory joint pain in patients with rheumatoid arthritis receiving biologics: a report of two cases. Joint Bone Spine. 2009 Mar;76(2):190-4. doi: 10.1016/j.jbspin.2008.05.006. Epub 2008 Oct 25.
20. Singh JA, Mahowald ML, Kushnaryov A, et al. Repeat injections of intra-articular botulinum toxin a for the treatment of chronic arthritis joint pain. J Clin Rheumatol. 2009 Feb;15(1):35-8. doi: 10.1097/RHU.0b013e3181953b14.
21. Singh JA, Mahowald ML, Noorbaloochi S. Intra-articular botulinum toxin A for refractory shoulder pain: a randomized, double-blinded, placebo-controlled trial. Transl Res. 2009 May;153(5):205-16. doi: 10.1016 /j.trsl.2009.02.004. Epub 2009 Mar 13.
22. Kidd BL. Osteoarthritis and joint pain. Pain. 2006 Jul;123(1-2):6-9. doi: 10.1016/j.pain.2006.04.009. Epub 2006 May 22.
23. Martell-Pelletier J, Barr AJ, Cicuttini FM, et al. Osteoarthritis. Nat Rev Dis Primers. 2016 Oct 13;2:16072. doi: 10.1038/nrdp.2016.72.
24. Ivanusic JJ. Molecular Mechanisms That Contribute to Bone Marrow Pain. Front Neurol. 2017 Sep 11;8:458. doi: 10.3389/fneur.2017.00458. eCollection 2017.
25. Khenioui H, Houvenagel E, Catanzariti JF, et al. Usefulness of intra-articular botulinum toxin injections. A systematic review. Joint Bone Spine. 2016 Mar;83(2):149-54. doi: 10.1016/j.jbspin.2015.10.001. Epub 2015 Nov 29.
26. Schaible HG, Ebersberger A, von Banchet GS. Mechanisms of pain in arthritis. Ann N Y Acad Sci. 2002 Jun;966: 343-54. doi: 10.1111/j.1749-6632.2002.tb04234.x.
27. Hsieh LF, Wu CW, Chou CC, et al. Effects of botulinum toxin landmark-guided intra-articular injection in subjects with knee osteoarthritis. PM R. 2016 Dec;8(12): 1127-35. doi: 10.1016/j.pmrj.2016.05.009. Epub 2016 May 19.
28. Chou CL, Lee SH, Lu SY, et al. Therapeutic effects of intra-articular botulinum neurotoxin in advanced knee osteoarthritis. J Chin Med Assoc. 2010 Nov; 73(11):573-80. doi: 10.1016/S1726-4901(10)70126-X.
29. Cinone N, Letizia S, Santoro L, et al. Intra-articular injection of botulinum toxin type A for shoulder pain in glenohumeral osteoarthritis: a case series summary and review of the literature. J Pain Res. 2018 Jun 25;11:1239-45. doi: 10.2147/JPR.S159700.eCollection 2018.
30. Joo YJ, Yoon SJ, Kim CW. A comparison of the short-term effects of a botulinum toxin type a and triamcinolone acetate injection on adhesive capsulitis of the shoulder. Ann Rehabil Med. 2013 Apr;37(2):208-14. doi: 10.5535/arm.2013.37.2.208. Epub 2013 Apr 30.
31. Sun SF, Hsu CW, Lin HS, et al. Efficacy of intraarticular botulinum toxin A and intraarticular hyaluronate plus rehabilitation exercise in patients with unilateral ankle osteoarthritis: a randomized controlled trial. J Foot Ankle Res. 2014 Feb 6;7(1):9. doi: 10.1186/1757-1146-7-9.
32. Singh JA, Mahowald ML, Noorbaloochi S. Intraarticular botulinum toxin A for refractory painful total knee arthroplasty: a randomized controlled trial. J Rheumatol. 2010 Nov; 37(11):2377-86. doi: 10.3899/jrheum.100336.Epub 2010 Sep 1.
33. Arendt-Nielsen L, Jiang G, De Gryse R, Turkel C. Intra-articular onabotulinumtoxin A in osteoarthritis knee pain: Effect on human mechanistic pain biomarkers and clinical pain. Scand J Rheumatol. 2017 Jul; 46(4):303-16. doi: 10.1080/03009742.2016.1203988. Epub 2016 Oct 13.
34. McAlindon TE, Schmidt U, Bugarin D, et al. Efficacy and safety of single-dose onabotulinumtoxinA in the treatment of symptoms of osteoarthritis of the knee: results of a placebo-controlled, double-blind study. Osteoarthritis Cartilage. 2018 Oct;26(10): 1291-9. doi: 10.1016/j.joca.2018.05.001. Epub 2018 May 9.
35. Plotnikova EV, El'kin VD, Mironov AN, et al. Experimental justification for the use of a new domestic immunobiological drug with a muscle relaxant effect «relatox» in cosmetic practice. Biologiya i ekperimental'naya meditsina. 2011;XXVIII(4):125-30. (In Russ.).
36. Batifol D. Different types of injection in temporomandibular disorders (TMD) treatment. Rev Stomatol Chir Maxillofac Chir Orale. 2016 Sep;117(4):256-8. doi: 10.1016/j.revsto.2016.07.005. Epub 2016 Aug 23.
37. Sycha T, Graninger M, Auff E, Shinider P. Botulinum toxin in the treatment of Raynaud phenomenon: A pilot study. Eur J Clin Invest. 2004 Apr;34(4):312-3. doi: 10.1111/j.1365-2362.2004.01324.x.
38. Asad U, Austin B, Tarbox M, Paulger B. Botulinum toxin in the long-term treatment of refractory Raynaud's phenomenon. J Drugs Dermatol. 2019 Sep 1;18(9):943-5.
39. Smith L, Polsky D, Franks AG Jr. Botulinum toxin-A for the treatment of Raynaud syndrome. Arch Dermatol. 2012 Apr; 148(4):426-8. doi: 10.1001/archdermatol.2011.1144.
40. Van Beek AL, Lim PK, Gear AJ, Pritzker MR. Management of vasospastic disorders with botulinum toxin. Plast Reconstr Surg. 2007 Jan;119(1):217-26. doi: 10.1097/01.prs.0000244860.00674.57.
41. Neumeister MW. Botulinum toxin type A in the treatment of Raynaud's phenomenon. J Hand Surg Am. 2010 Dec;35(12):2085-92. doi: 10.1016/j.jhsa.2010.09.019.
42. Bello RJ, Cooney CM, Melamed E, et al. The therapeutic efficacy of botulinum toxin in treating scleroderma-associated Raynaud's phenomenon: a randomized, double-blind, placebo-controlled clinical trial. Arthritis Rheumatol. 2017 Aug;69(8):1661-9. doi: 10.1002/art.40123. Epub 2017 Jun 26.
43. Serri J, Legre R, Veit V, et al. Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis. Ann Chir Plast Esthet. 2013 Dec;58(6): 658-62. doi: 10.1016/j.anplas.2011.11.001.Epub 2011 Dec 26.
44. Motegi S, Yamada K, Toki S, et al. Beneficial effect of botulinum toxin A on Raynaud's phenomenon in Japanese patients with systemic sclerosis: a prospective, case series study. J Dermatol. 2016 Jan;43(1): 56-62. doi: 10.1111/1346-8138.13030. Epub 2015 Jul 15.
45. Medina S, Gomez-Zubiaur A, Valdeolivas-Casillas N, et al. Botulinum toxin type A in the treatment of Raynaud's phenomenon: a three-year follow-up study. Eur J Rheumatol. 2018 Dec;5(4):224-9. doi: 10.5152/eurjrheum.2018.18013. Epub 2018 Oct 12.
46. Herrick AL. The pathogenesis, diagnosis and treatment of Raynaud phenomenon. Nat Rev Rheumatol. 2012 Aug;8(8):469-79. doi: 10.1038/nrrheum.2012.96. Epub 2012 Jul 10.
47. Wigley FM. Clinical practice Raynaud's phenomenon. N Engl J Med. 2002 Sep 26; 347(13):1001-8. doi: 10.1056/NEJMcp013013.
48. Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain. 2004 Jan;107(1-2):125-33. doi: 10.1016/j.pain.2003.10.008.
49. Stone AV, Koman AL, Callahan MF, et al. The effect of botulinum neurotoxin-A on blood flow in rats: a potencial mechanism for treatment of Raynaud phenomenon. J Hand Surg Am. 2012 Apr;37(4):795-802. doi: 10.1016/j.jhsa.2012.01.021. Epub 2012 Mar 3.
50. Setler P. Therapeutic use of botulinum toxins: back-ground and history. Clin J Pain. Nov-Dec 2002;18(6 Suppl):S119-24. doi: 10.1097/00002508-200211001-00002.
51. O'Neil LM, Palme CE, Riffat F, Mahant N. Botulinum toxin for the management of Sjö gren syndrome-associated recurrent parotitis. J Oral Maxillofac Surg. 2016 Dec; 74(12):2428-30. doi: 10.1016/j.joms.2016.06.169. Epub 2016 Jun 18.
52. Daniel SJ, Diamond M. Botulinum toxin injection: a novel treatment for recurrent cystic parotitis Sjö gren syndrome. Otolaryngol Head Neck Surg. 2011 Jul;145(1):180-1. doi: 10.1177/0194599811398596.
53. Spiera H, Asbell PA, Simpson DM. Botulinum toxin increases tearing in patients with Sjö gren's syndrome: a preliminary report. J Rheumatol. 1997 Sep;24(9):1842-3.
54. Francis IC, Coroneo MT. Botulinum toxin increases tearing in patients with Sjö gren's syndrome: a preliminary report. J Rheumatol. 1998 Sep;25(9):1859.
Review
For citations:
Egorova ON, Belov BS, Sazhina EG. Use of botulinum toxin type A in rheumatic diseases. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2021;15(5):108-113. (In Russ.) https://doi.org/10.14412/1996-7012-2021-5-108-113
Views:
1376
Email this article 